No Data
The U.S.-Iran peace talks failed to reach an agreement, leading to a subdued market sentiment.
[Emerging Market Stock Strategy] The emerging market is expected to remain subdued today. In the U.S. stock market on the 10th, the Dow Jones Industrial Average fell by 269.23 points (-0.56%) to 47,916.57, marking its first decline in three days. While the lower-than-expected core Consumer Price Index (CPI) provided some support for stock prices, warnings from President Trump regarding potential renewed attacks in the event of a negotiation breakdown led to a rise in crude oil and long-term interest rates, contributing to the Dow’s continued decline. Meanwhile, the Nasdaq remained firm throughout the day, supported by strong performance in the semiconductor sector.
SNS, LTS, and others
Company code <3967> ELTES has revised its earnings forecast, with the previous fiscal year's projected operating profit adjusted to 4.30 billion yen from 3.80 billion yen. Company code <4076> CNS upwardly revised its forecast, with the current fiscal year's projected operating profit now at 7.10 billion yen, up from 6.58 billion yen, along with an increased dividend; the year-end dividend per share remains unchanged at 55.00 yen. Company code <4889> Renascience announced the results of Phase II clinical trials for RS5614, a PAI-1 inhibitor targeting interstitial lung disease associated with systemic sclerosis (SSc-ILD). Company code <4892> Cyfuse is developing new treatments in the dental field.
Yaskawa Electric reported a 5.7% decrease in operating profit to 47.3 billion yen for the fiscal year ending February 26, while projecting a 26.8% increase to 60 billion yen for the next fiscal year ending February 27.
Yaskawa Electric <6506> announced its consolidated financial results for the fiscal year ending February 2026, reporting a 0.8% year-on-year increase in revenue to 542.122 billion yen and a 5.7% decrease in operating income to 47.307 billion yen. Revenue increased compared to the previous fiscal year, as new orders were effectively converted into sales, contributing to the normalization of the order backlog. Although added value increased due to higher sales, operating income declined year-on-year as the impact of foreign exchange rates and rising indirect costs could not be fully offset.
CNS: Supplementary Explanation Materials for the Third Quarter Results of the Fiscal Year Ending May 2026
CNS: Notice Regarding the Revision of Full-Year Earnings Forecast (Upward Revision) and Dividend Forecast (Increase in Dividends)
CNS: Third Quarter Earnings Briefing for the Fiscal Year Ending May 2026 (Japanese GAAP, Consolidated)